BIOVENTUS INC.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $568.1M | $573.3M | $512.3M | $512.1M | $430.9M | $321.2M | $340.1M |
| Cost of Revenue | $179.9M | $185.1M | $184.2M | $181.0M | $128.2M | $87.6M | $90.9M |
| Gross Profit | $388.2M | $388.2M | $328.2M | $331.1M | $302.7M | $233.5M | $249.2M |
| Gross Margin | 68.3% | 67.7% | 64.1% | 64.6% | 70.3% | 72.7% | 73.3% |
| Operating Expenses | |||||||
| Research & Development | $12.1M | $14.0M | $13.4M | $23.9M | $19.0M | $11.2M | $11.1M |
| SG&A Expense | $314.0M | $343.8M | $303.9M | $332.1M | $254.3M | $193.1M | $198.5M |
| Operating Income | $54.0M | $-15.2M | $-81.7M | $-167.2M | $12.1M | $21.2M | $31.2M |
| Operating Margin | 9.5% | -2.7% | -16.0% | -32.7% | 2.8% | 6.6% | 9.2% |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | $25.7M | $-52.3M | $-121.1M | $-189.0M | $9.5M | $15.9M | $9.7M |
| Income Tax Expense | $-1.6M | $-5.3M | $85.0K | $-44.4M | $-2.0M | $1.2M | $1.6M |
| Net Income | $22.7M | $-36.1M | $-156.2M | $-158.7M | $19.4M | $16.4M | $6.9M |
| Net Margin | 4.0% | -6.3% | -30.5% | -31.0% | 4.5% | 5.1% | 2.0% |
| EPS (Basic) | $0.34 | $-0.56 | $-2.49 | $-2.59 | $-0.15 | — | — |
| EPS (Diluted) | $0.33 | $-0.56 | $-2.49 | $-2.59 | $-0.15 | — | — |
| Shares Outstanding (Basic) | 66.6M | 64.5M | 62.6M | 61.4M | 45.5M | — | — |
| Shares Outstanding (Diluted) | 68.9M | 64.5M | 62.6M | 61.4M | 45.5M | — | — |
| Dividends Per Share | — | — | — | — | — | — | — |